Biomarin Pharmaceutical Inc (BMRN)
66.60
+0.71
(+1.08%)
USD |
NASDAQ |
Nov 01, 16:00
66.60
0.00 (0.00%)
After-Hours: 20:00
Biomarin Pharmaceutical Enterprise Value: 12.36B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 12.36B |
| October 31, 2024 | 12.22B |
| October 30, 2024 | 12.37B |
| October 29, 2024 | 12.99B |
| October 28, 2024 | 13.03B |
| October 25, 2024 | 12.95B |
| October 24, 2024 | 13.08B |
| October 23, 2024 | 13.00B |
| October 22, 2024 | 13.10B |
| October 21, 2024 | 13.06B |
| October 18, 2024 | 13.02B |
| October 17, 2024 | 12.90B |
| October 16, 2024 | 13.03B |
| October 15, 2024 | 13.09B |
| October 14, 2024 | 13.05B |
| October 11, 2024 | 13.07B |
| October 10, 2024 | 12.97B |
| October 09, 2024 | 12.96B |
| October 08, 2024 | 12.75B |
| October 07, 2024 | 12.80B |
| October 04, 2024 | 12.91B |
| October 03, 2024 | 12.65B |
| October 02, 2024 | 12.94B |
| October 01, 2024 | 13.02B |
| September 30, 2024 | 13.06B |
| Date | Value |
|---|---|
| September 27, 2024 | 13.30B |
| September 26, 2024 | 13.24B |
| September 25, 2024 | 13.00B |
| September 24, 2024 | 13.09B |
| September 23, 2024 | 13.03B |
| September 20, 2024 | 13.32B |
| September 19, 2024 | 13.46B |
| September 18, 2024 | 13.41B |
| September 17, 2024 | 13.30B |
| September 16, 2024 | 13.16B |
| September 13, 2024 | 16.03B |
| September 12, 2024 | 15.93B |
| September 11, 2024 | 16.01B |
| September 10, 2024 | 16.02B |
| September 09, 2024 | 15.92B |
| September 06, 2024 | 15.87B |
| September 05, 2024 | 16.07B |
| September 04, 2024 | 16.97B |
| September 03, 2024 | 17.30B |
| August 30, 2024 | 17.23B |
| August 29, 2024 | 17.26B |
| August 28, 2024 | 17.06B |
| August 27, 2024 | 17.09B |
| August 26, 2024 | 17.00B |
| August 23, 2024 | 17.00B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
12.22B
Minimum
Oct 31 2024
23.80B
Maximum
Jul 20 2020
16.08B
Average
15.90B
Median
Jun 14 2024
Enterprise Value Benchmarks
| Merck & Co Inc | 284.75B |
| Bristol-Myers Squibb Co | 151.89B |
| Alnylam Pharmaceuticals Inc | 33.57B |
| Bioventus Inc | 1.273B |
| Moderna Inc | 12.51B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 106.08M |
| Revenue (Quarterly) | 745.74M |
| Total Expenses (Quarterly) | 631.87M |
| EPS Diluted (Quarterly) | 0.55 |
| Gross Profit Margin (Quarterly) | 74.73% |
| Profit Margin (Quarterly) | 14.22% |
| Earnings Yield | 2.51% |
| Operating Earnings Yield | 2.39% |
| Normalized Earnings Yield | 2.444 |